Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935514 · ClinicalTrials.gov registry record · NA
Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring
A NA study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- NA
- Development phase
- 152
- Enrollment target
NCT05935514: Completed NA study, sponsored by Pennington Biomedical Research Center.
NCT05935514 is a NA study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 152 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05935514, a NA study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
Study Summary
This study is a randomized clinical trial with the primary aim examining the efficacy of a novel integrated solution of a digitally delivered behavioral weight management program tailored for diabetes utilizing a continuous glucose monitor (CGM) built into the WW digital platform for adults with type 2 diabetes (T2D) for the reduction of HbA1c.
Primary Outcome
Hemoglobin A1c levels (%) are measured using standard laboratory methods
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL WW Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2023-08-22 |
| Est. Completion | 2025-10-23 |
| Phase | NA |
What the finished NCT05935514 record still lists
NCT05935514 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT05935514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05935514 about?
NCT05935514 is a clinical study titled "Improving Glycemic Control Using a Virtual Weight Control Program and Continuous Glucose Monitoring". This study is a randomized clinical trial with the primary aim examining the efficacy of a novel integrated solution of a digitally delivered behavioral weight management program tailored for diabetes utilizing a continuous glucose monitor (CGM) built into the WW digital platform for adults with typ...
What is the current status of trial NCT05935514?
This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2023-08-22. Estimated completion is 2025-10-23.
What interventions are being tested in trial NCT05935514?
The interventions under investigation include: Usual Care (BEHAVIORAL), WW Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05935514?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05935514's enrollment target sits among peer trials
152 658th of 2000 higher than 1,340 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI